Estrogenic substance and Breast cancer metastatic - a phase IV clinical study of FDA data

Summary:

Breast cancer metastatic is found among people who take Estrogenic substance, especially for people who are 50-59 old.

The phase IV clinical study analyzes which people take Estrogenic substance and have Breast cancer metastatic. It is created by eHealthMe based on reports of 791 people who have side effects when taking Estrogenic substance from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 26, 2022

791 people reported to have side effects when taking Estrogenic substance.
Among them, 15 people (1.9%) have Breast cancer metastatic.


What is Estrogenic substance?

Estrogenic substance has active ingredients of estrone. It is often used in menopause. eHealthMe is studying from 865 Estrogenic substance users for its effectiveness, alternative drugs and more.

What is Breast cancer metastatic?

Breast cancer metastatic is found to be associated with 898 drugs and 457 conditions by eHealthMe.

Number of Estrogenic substance and Breast cancer metastatic reports submitted per year:

Could Estrogenic substance cause Breast cancer metastatic?

Age of people who have Breast cancer metastatic when taking Estrogenic substance *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 28.57 %
  • 50-59: 71.43 %
  • 60+: 0.0 %

Common drugs people take besides Estrogenic substance *:

  1. Prempro: 14 people, 93.33%
  2. Provera: 13 people, 86.67%
  3. Premarin: 12 people, 80.00%
  4. Medroxyprogesterone Acetate: 9 people, 60.00%
  5. Cycrin: 6 people, 40.00%
  6. Premphase: 1 person, 6.67%
  7. Lipitor: 1 person, 6.67%
  8. Hyzaar: 1 person, 6.67%
  9. Cenestin: 1 person, 6.67%
  10. Activella: 1 person, 6.67%

Common side effects people have besides Breast cancer metastatic *:

  1. Herpes Zoster: 2 people, 13.33%
  2. Metastases To Spine (cancer spreads to spine): 1 person, 6.67%
  3. Metastases To Lymph Nodes (cancer spreads to lymph node): 1 person, 6.67%
  4. Metastases To Bone (cancer spreads to bone): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Estrogenic substance and have Breast cancer metastatic?

Check whether Breast cancer metastatic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Breast cancer metastatic and when was it recovered:

Expand to all the drugs that have ingredients of estrone:

Alternative drugs to, pros and cons of Estrogenic substance:

Breast cancer metastatic treatments and more:

COVID vaccines that are related to Breast cancer metastatic:

Common drugs associated with Breast cancer metastatic:

All the drugs that are associated with Breast cancer metastatic:

Common conditions associated with Breast cancer metastatic:

All the conditions that are associated with Breast cancer metastatic:

How the study uses the data?

The study uses data from the FDA. It is based on estrone (the active ingredients of Estrogenic substance) and Estrogenic substance (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: